Microwave Thermotherapy

Prior authorization: tumor characteristics and intent

Prior authorization may be required for microwave thermotherapy procedures depending on the service code and the member’s plan. When requesting prior authorization, document tumor characteristics (size, location, number of lesions) and the clinical intent of the procedure (curative, palliative, limb-sparing, pain control, or other intent). Provide prior-authorization reviewers with tumor measurements, imaging reports, and a statement of treatment intent to support clinical review.

• Document tumor size, location, number of lesions, and clinical intent on the prior authorization request.
• Confirm whether specific CPT/HCPCS codes referenced in the policy require prior authorization under the member’s benefit plan.

Prior authorization

Prior authorization: confirm requirements with the payer and include supporting clinical documentation. If uncertain about whether a given CPT/HCPCS code for microwave procedures is covered, contact Aetna’s provider services or use the plan’s authorization portal to verify coverage and obtain any required approvals prior to scheduling.

• Include relevant ICD-10 diagnosis codes when requesting authorization.
• If applicable, attach prior imaging, pathology, and prior treatment history (e.g., prior chemotherapy, radiation, BCG) to the authorization submission.

Denial risk for experimental/investigational indications

Procedures and indications listed in this policy (for example: bladder cancer, bone cancer/limb salvage, chronic low back/neck pain, kidney cancer, osteosarcoma, and others) are considered experimental and investigational by Aetna for the listed indications and therefore are at high risk for denial when requested for these purposes.

• Expect denial risk for microwave thermotherapy when used to treat indications listed as experimental/investigational (see policy list).
• If proposing use outside listed indications, provide high-quality evidence and rationale; anticipate case-by-case medical review.

Guideline absence may trigger review

Absence of microwave thermotherapy from major guideline statements (e.g., EAU, NCCN) may prompt additional review or denial. Provide evidence-based justification if requesting coverage for indications not supported by these guidelines.

• When guidelines do not mention the therapy, include peer-reviewed studies, systematic reviews, or RCT data to justify medical necessity.
• For bladder cancer (NMIBC) consider including details on sequencing relative to BCG and other standard therapies.

No explicit authorization or denial triggers in policy text

The policy text does not specify explicit authorization or denial triggers (e.g., no numeric tumor-size cutoffs or mandated prior therapy sequences are listed). Authorization decisions will therefore be based on submitted clinical documentation and medical review.

• Because explicit triggers are not provided, ensure completeness of records: imaging, pathology, prior treatments, and rationale for selecting microwave therapy.
• Authorization outcomes are determined by clinical review; absence of detailed policy thresholds does not imply routine approval.

No documentation requirements specified in these chunks

No additional or alternative documentation requirements are specified in the provided policy chunks beyond standard prior-authorization submissions and clinical records. Follow payer-specific submission instructions and contact the plan for any additional required forms.

• If plan-specific documentation rules exist (not included here), follow those instructions.
• When in doubt, submit comprehensive clinical records to support medical necessity.

Coding and diagnosis documentation

When billing, include appropriate CPT/HCPCS and ICD-10 codes and document the diagnoses that justify the procedure. The policy contains lists of CPT/HCPCS/ICD-10 codes relevant to microwave thermotherapy—ensure claims include the correct diagnosis pointers and any required modifiers.

• Attach imaging and operative reports that corroborate the diagnosis codes on the claim.
• Verify each CPT/HCPCS used is appropriate for the billed indication and supported by documentation.

Required clinical documentation

Required clinical documentation to support authorization/medical review includes pre-procedure imaging, peri-procedural and immediate post-procedure imaging (when applicable), and follow-up imaging schedules. For example studies referenced in the policy used imaging at pre-ablation and at 1 day, 1 month, 3 months, then every 6 months post-ablation to document initial ablation success and ongoing control.

• Provide imaging reports (CT/MR/CEUS) demonstrating tumor size and location pre-procedure.
• Include post-procedure imaging and planned surveillance schedule to document treatment response.

Therapeutic sequencing considerations for NMIBC

Therapeutic sequencing: for non–muscle-invasive bladder cancer (NMIBC), chemo-hyperthermia (microwave-induced hyperthermia combined with intravesical chemotherapy) has been studied as an adjunct to intravesical chemotherapy and in settings where BCG is contraindicated or when patients are unsuitable for cystectomy. Document prior intravesical treatments (e.g., MMC, BCG), tumor recurrence history, and reason for selecting chemo-hyperthermia.

• Indicate whether chemo-hyperthermia is being used as first-line adjuvant therapy, salvage therapy after BCG failure, or for BCG-contraindicated patients.
• Provide recurrence history, prior treatment dates, and response to prior therapies.

Non-oncologic conservative therapy precedence

For non-oncologic indications such as chronic low back or neck pain, randomized trials cited in the policy found no added benefit of therapeutic microwave diathermy over exercise and education. Prioritize conservative therapies (exercise programs, education) before considering microwave approaches for these conditions and document prior conservative therapy attempts.

• Document prior conservative treatments (physical therapy, exercise programs, medications) and their outcomes when requesting coverage for pain-related indications.
• Note that RCT evidence did not demonstrate superiority of microwave diathermy compared with exercise/education.